Pharmacological Chaperone Therapy for Pompe Disease

Area of Science:

• Biochemistry and Genetics
• Lysosomal Storage Diseases
• Pharmacology

Background:

• Pompe disease (PD) results from GAA gene mutations, leading to acid alpha-glucosidase (GAA) deficiency.
• This deficiency causes glycogen accumulation in lysosomes, affecting muscle and nerve cells.
• Current treatment, enzyme replacement therapy (ERT), has limitations.

Purpose of the Study:

• To review pharmacological chaperones (PCs) as a novel therapeutic strategy for Pompe disease.
• To categorize PCs into active site-specific chaperones (ASSCs) and non-inhibitory types.
• To highlight the combined use of PCs with ERT.

Main Methods:

• Literature review of reported pharmacological chaperones for Pompe disease.
• Classification of identified PCs based on their mechanism of action (ASSC vs. non-inhibitory).
• Analysis of studies investigating the efficacy of PCs, particularly in combination with ERT.

Main Results:

• Various pharmacological chaperones have been identified for Pompe disease.
• These PCs function by stabilizing the deficient GAA enzyme.
• Emerging data suggests potential benefits from combining PC therapy with ERT.

Conclusions:

• Pharmacological chaperones represent a promising therapeutic avenue for Pompe disease.
• Further research into PC mechanisms and combination strategies is warranted.
• These novel approaches may overcome limitations associated with current ERT.